Long Non-Coding RNA PVT1 Regulates BAMBI to Promote Tumor Progression in Non-Small Cell Lung Cancer by Sponging miR-17-5p Corrigendum

Source: OncoTargets and Therapy - Category: Cancer & Oncology Tags: OncoTargets and Therapy Source Type: research

Related Links:

Authors: Samejima Y, Iuchi A, Kanai T, Noda Y, Nasu S, Tanaka A, Morishita N, Suzuki H, Okamoto N, Harada H, Ezumi A, Ueda K, Kawahara K, Hirashima T Abstract Cardiac side effects associated with immune checkpoint inhibitors (ICIs) are an uncommon but serious complication with a relatively high mortality. We experienced a case of cardiomyopathy induced by nivolumab. Echocardiography showed diffuse hypo-kinesis of the left ventricular cardiac wall and a significant decrease in the ejection fraction, like dilated cardiomyopathy. The myocardial biopsy showed non-inflammatory change; cardiac function gradually improved...
Source: Internal Medicine - Category: Internal Medicine Tags: Intern Med Source Type: research
Authors: Jeon H, Eo W, Shim B, Kim S, Lee S Abstract Objectives: The impact of health-related quality of life (HRQoL) on survival has been investigated in patients with various cancers. Here, we evaluated the prognostic value of HRQoL using the Functional Assessment of Cancer Therapy-General (FACT-G) in advanced non-small-cell lung cancer (NSCLC) patients treated with Korean medicine. Methods: A retrospective review of medical records and FACT-G scores of patients with advanced NSCLC who received treatment with Korean medicine was conducted. The reliability of the FACT-G was determined using Cronbach's alpha an...
Source: Evidence-based Complementary and Alternative Medicine - Category: Complementary Medicine Tags: Evid Based Complement Alternat Med Source Type: research
Publication date: Available online 26 May 2020Source: Journal of Vascular and Interventional RadiologyAuthor(s): Toshihiro Iguchi, Takao Hiraki, Yusuke Matsui, Toshiharu Mitsuhashi, Norihisa Katayama, Kuniaki Katsui, Junichi Soh, Jun Sakurai, Hideo Gobara, Shinichi Toyooka, Susumu Kanazawa
Source: Journal of Vascular and Interventional Radiology - Category: Radiology Source Type: research
Publication date: Available online 25 May 2020Source: Pharmacological ResearchAuthor(s): Ya-Jia Xie, Wei-Na Gao, Qi-Biao Wu, Xiao-Jun Yao, Ze-Bo Jiang, Yu-Wei Wang, Wen-Jun Wang, Wei Li, Shahid Hussain, Liang Liu, Elaine Lai-Han Leung, Xing-Xing Fan
Source: Pharmacological Research - Category: Drugs & Pharmacology Source Type: research
Approximately 5% of non-small cell lung cancers (NSCLC) harbor an anaplastic lymphoma kinase (ALK) rearrangement. Several ALK tyrosine kinase inhibitors (TKI) have demonstrated their efficacy as first line treatment for advanced ALK-positive NSCLC (1). However, patients treated with these drugs eventually develop acquired TKI resistance and tumor progression, and the question of the therapeutic options beyond ALK TKI resistance remains a critical issue. Since 2014, immune checkpoint inhibitors (ICI) have become a major treatment in advanced NSCLC.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
Conclusions: The abnormal expression of ALAS1 is closely related to the proliferation and metastasis of CRC cells, suggesting that ALAS1 may be a novel therapeutic target for the treatment of CRC.
Source: The Saudi Journal of Gastroenterology - Category: Gastroenterology Authors: Source Type: research
Serum miRNAs expression levels and CT texture features could be combined to develop radiotranscriptomics signature for independently predicting radiotherapy response. Radiotranscriptomics signature ‐based nomogram was constructed for objective response rates. The statistical significance between serum miRNAs levels and CT texture features was preliminarily explored. AbstractPurposeWe aimed to establish radiotranscriptomics signatures based on serum miRNA levels and computed tomography (CT) texture features and develop nomogram models for predicting radiotherapy response in patients with nonsmall cell lung cancer (NSCLC)....
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
Indoleamine 2,3-dioxygenase 2 (IDO2) is an analog of the tryptophan degrading and immunomodulating enzyme indoleamine 2,3-dioxygenase 1 (IDO1). Although the role of IDO1 is largely understood, the function of IDO2 is not yet well-elucidated. IDO2 overexpression was documented in some human tumors, but the linkage between IDO2 expression and cancer progression is still unclear, in particular in non-small cell lung cancer (NSCLC). Immunohistochemical expression and cellular localization of IDO2 was evaluated on 191 formalin-fixed and paraffin-embedded resected NSCLC. Correlations between IDO2 expression, clinical-pathologica...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
Abstract Non-small lung cancer (NSCLC) is the most common cancer in the world. The epidermal growth factor receptor (EGFR) gene is mutated in approximately 10% of lung cancer cases in the US and 50% of lung cancer in Asia. The representative target therapeutic agent, erlotinib (EGFR tyrosine kinase inhibitor; EGFR TKI), is effective in inactivating EGFR in lung cancer patients. However, approximately 50-60% of patients are resistant to EGFR TKI. These populations are associated with the EGFR mutation. To overcome resistance to EGFR TKI, we discovered a JAK1 inhibitor, CJ14939. We investigated the efficacy of CJ149...
Source: Biochemical and Biophysical Research communications - Category: Biochemistry Authors: Tags: Biochem Biophys Res Commun Source Type: research
AstraZeneca to Leverage ArcherDX's PCM Liquid Biopsy Technology to Facilitate Multiple Clinical Trials for Early-Stage Non-Small Cell Lung Cancer Therapies BOULDER, Colo., May 26, 2020 -- (Healthcare Sales &Marketing Network) -- ArcherDX, Inc., today ... Biopharmaceuticals, Diagnostics, Oncology ArcherDX, AstraZeneca, Anchored Multiplex PCR, Personalized Cancer Monitoring
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | Lung Cancer | Non-Small Cell Lung Cancer